DEFERRED TREATMENT IN CLINICALLY LOCALIZED PROSTATIC-CARCINOMA

被引：104

作者：

ADOLFSSON, J

CARSTENSEN, J

LOWHAGEN, T

机构：

[1] KAROLINSKA HOSP,DEPT PATHOL,DIV CLIN CYTOL,S-10401 STOCKHOLM 60,SWEDEN

[2] LINKOPING UNIV HOSP,DEPT UROL,S-58185 LINKOPING,SWEDEN

来源：

BRITISH JOURNAL OF UROLOGY | 1992年 / 69卷 / 02期

关键词：

D O I：

10.1111/j.1464-410X.1992.tb15493.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A series of 122 patients with a cytological diagnosis of well or moderately differentiated and clinically localised (T1-2) prostatic carcinoma were followed up without any initial anti-tumour therapy. The median observation time was 91 months. During follow-up the local tumour progressed to stage T3 in 67 patients (55%) and distant metastases developed in 17 (14%); 47 patients died (38%), 9 of them (7%) from prostatic carcinoma. The risk of dying from prostatic carcinoma was 1% after 5 years and 16% after 10 years for patients not dying from other causes.

引用

页码：183 / 187

页数：5

共 8 条

[1] THE NATURAL COURSE OF LOW-GRADE, NONMETASTATIC PROSTATIC-CARCINOMA [J].

ADOLFSSON, J ;

RONSTROM, L ;

CARSTENSEN, J ;

LOWHAGEN, T ;

HEDLUND, PO .

BRITISH JOURNAL OF UROLOGY, 1990, 65 (06) :611-614

[2]

BERKSON J, 1950, P STAFF M MAYO CLIN, V25, P270

[3]

COX DR, 1972, J R STAT SOC B, V34, P187

[4]

ESPOSTI P L, 1971, Scandinavian Journal of Urology and Nephrology, V5, P199, DOI 10.3109/00365597109133601

[5]

GEORGE NJR, 1988, LANCET, V1, P494

[6]

JOHANSSON JE, 1989, LANCET, V1, P799

[7]

WHITMORE WF, 1984, UROL CLIN N AM, V11, P205

[8]

1978, TNM CLASSIFICATION M

← 1 →